JMP Securities initiated coverage on shares of TELA Bio (NASDAQ:TELA) in a research note published on Tuesday, Benzinga reports. The firm issued an outperform rating and a $22.00 price target on the stock.
A number of other brokerages have also issued reports on TELA. Canaccord Genuity began coverage on shares of TELA Bio in a research note on Tuesday. They set a buy rating and a $19.00 price target on the stock. Piper Jaffray Companies started coverage on shares of TELA Bio in a report on Tuesday. They set an overweight rating and a $17.00 price target for the company.
TELA stock opened at $12.96 on Tuesday. TELA Bio has a one year low of $10.78 and a one year high of $15.05.
About TELA Bio
TELA Bio, Inc, a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. It offers reinforced tissue matrix products for a variety of reconstruction procedures, including hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.
Featured Article: Outstanding Shares and The Effect on Share Price
Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.